Table 2 from Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma
收藏Figshare2025-06-03 更新2026-04-28 收录
下载链接：
https://figshare.com/articles/dataset/Table_2_from_Phase_I_Study_of_the_Mutant_i_IDH1_i_Inhibitor_Ivosidenib_Long-term_Safety_and_Clinical_Activity_in_Patients_with_Conventional_Chondrosarcoma/29221826
下载链接
链接失效反馈官方服务：
资源简介：
Most frequently reported AEs in >15% of patients with CS receiving ivosidenib.
创建时间：
2025-06-03
